一分钟看懂
这是一项关于白血病的III 期研究，登记的药物或干预包括Ibrutinib，当前状态为研究进行中，已停止招募。登记地点显示中国北京、成都、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ibrutinib · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录4项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出3项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University People's Hospital · 北京
- Peking University Third Hospital · 北京
- Peking University First Hospital · 北京
- West China Hospital Sichuan University · 成都
- Fujian Medical University · 福州
- Sun Yat-sen University Cancer Hospital · 广州
- Zhejiang University First Hospital · 杭州
- Ruijin Hospital · 上海
- Tangdu hospital the Fourth Military Medical · 山西省
- The First Affliated Hospital of Soochow University · 苏州
- The Institute of Hematological disease · 天津
- Wuhan Union Hospital · 武汉
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participants must be currently participating in an ibrutinib clinical study considered complete and have received at least 6 months of treatment with ibrutinib. At study entry, participants must be actively receiving treatment with single-agent ibrutinib; or participants must have participated in an ibrutinib randomized clinical study in which they initially received comparator treatment and now cross-over to ibrutinib. Note: A minimum of 6 months requirement for prior ibrutinib treatment will not be mandatory in this case and participants with less than 6 months will be required to have more frequent initial safety assessments; or participants must be currently participating in study PCI-32765LYM1002. At study entry, participants must be actively receiving combination treatment with ibrutinib and nivolumab or single-agent ibrutinib
- * Investigator's assessment that the benefit of continued ibrutinib therapy as a single agent or in combination with nivolumab will outweigh the risks
- * Agrees to protocol-defined use of effective contraception
- * Negative blood or urine pregnancy test at screening
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT01804686；登记信息更新于 2026-10-01；本站同步于 2026-10-08。